Short view..from:The New England Journal of Medicine
Andexanet Alfa for Bleeding Associated With Factor Xa Inhibitors
TAKE-HOME MESSAGE
In a total of 352 patients with major bleeding (primarily intracranial or gastrointestinal bleeding) associated with factor Xa inhibitors who subsequently received andexanet alfa, there was a greater than 90% reduction in anti–factor Xa activity for patients who had previously received either rivaroxaban or apixaban. Excellent or good hemostasis was achieved in 82% of evaluable patients.
Andexanet alfa was associated with good or excellent hemostasis in a majority of patients with major bleeding with factor Xa inhibitors.
– Eric Fountain, MD, MA
